Our findings indicate that MAGT1 is frequently upregulated in breast cancer and correlates with aggressive tumor behavior and poor clinical outcomes. MAGT1 promotes key oncogenic phenotypes in breast cancer cells and may influence the immune landscape, highlighting its potential as both a prognostic biomarker and a promising therapeutic target.

1 day ago

Journal • BRCA Biomarker

HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset) • CDH1 (Cadherin 1) • AGT (Angiotensinogen)

HER-2 mutation

The use of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) to guide treatment selection in metastatic breast cancer. (PubMed, Pharmacogenomics)

Actionable genomic mutations such as PIK3CA, ESR1, ERBB2, BRCA1/2, and AKT/PTEN are reviewed in relation to their corresponding therapeutic agents. Implementation challenges, pre-analysis pitfalls, uncertain sampling cadence, cost barriers, and disparities in access are discussed, along with potential solutions.

1 day ago

Review • Journal • BRCA Biomarker • Circulating tumor DNA

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog)

BRCA2 mutation • BRCA1 mutation • PIK3CA mutation • HER-2 mutation • PTEN mutation

Hallmarks of liver cancer: Therapeutic implications. (PubMed, Cell)

Unlike HCC, roughly 45% of iCCA harbor alterations amenable to precision oncology approaches, including fibroblast growth factor receptor 2 (FGFR2) fusions, isocitrate dehydrogenase 1 (IDH1) mutations, ERBB2 alterations, and BRAF mutations. In this review, we explore how this framework has reshaped liver cancer care and discuss the resulting breakthroughs in management and emerging directions that may further improve therapeutic strategies.

4 days ago

Review • Journal • IO biomarker

HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)

BRAF mutation • HER-2 mutation • IDH1 mutation • FGFR2 mutation • FGFR2 fusion

HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study. (PubMed, ESMO Gastrointest Oncol)

Of note, 6/7 cases with HER-2 mutations exhibited limited benefit from treatment with FOLFIRI plus cetuximab with PFS inferior to 8 months. Taken together, these results highlight the need to test HER-2 gene alterations for patients with RAS/BRAF V600 WT, MSS mCRC, who are candidates for anti-epidermal growth factor receptor therapies.

5 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)

HER-2 positive • HER-2 overexpression • BRAF mutation • HER-2 amplification • HER-2 negative • BRAF V600 • HER-2 mutation • BRAF wild-type • HER-2 positive + HER-2 overexpression

FoundationOne® CDx

Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium

Bifocal cerebellar liponeurocytoma with atypical features: A case report and a literature review. (PubMed, Clin Neuropathol)

The patient has been under observation without any further intervention for 70 months since diagnosis, with no evidence of disease recurrence. In addition to the rarity of cLNC, this is a unique case in terms of bifocality, anaplastic histology, and the described genetic abnormalities.

5 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)

TP53 mutation • PIK3CA mutation • HER-2 mutation

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study (clinicaltrials.gov)

P3, N=838, Active, not recruiting, SWOG Cancer Research Network | Trial primary completion date: Jan 2027 --> Nov 2025

5 days ago

Trial primary completion date

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF mutation • HER-2 mutation • MET mutation

Keytruda (pembrolizumab) • Cyramza (ramucirumab)

SOHO-02: A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) (clinicaltrials.gov)

P3, N=444, Recruiting, Bayer | N=174 --> 444

5 days ago

Enrollment change

HER-2 (Human epidermal growth factor receptor 2)

HER-2 mutation

Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Hyrnuo (sevabertinib)

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors (clinicaltrials.gov)

P1, N=25, Recruiting, Daiichi Sankyo

7 days ago

New P1 trial

HER-2 positive • HER-2 mutation

Enhertu (fam-trastuzumab deruxtecan-nxki) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment (clinicaltrials.gov)

P3, N=416, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting

7 days ago

Enrollment closed

HER-2 (Human epidermal growth factor receptor 2)

EGFR mutation • HER-2 mutation

Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Hernexeos (zongertinib)

Molecular and clinical disparity of EGFR-mutant non-small cell lung cancer (NSCLC) based on histopathological stage and EGFR molecular subtypes. (PubMed, Transl Lung Cancer Res)

ALK and FANCA were linked to increased hazard, while EP300 and PIK3R1 mutations correlated with improved prognosis. Given the growing importance of biomarker-driven treatment in the field of oncology, our results collectively open up new therapeutic opportunities for ES NSCLC patients.

8 days ago

Journal

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • ABL1 (ABL proto-oncogene 1) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • JAK2 (Janus kinase 2) • mTOR (Mechanistic target of rapamycin kinase) • FGFR4 (Fibroblast growth factor receptor 4) • ATRX (ATRX Chromatin Remodeler) • FANCA (FA Complementation Group A) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • STAG2 (Stromal Antigen 2) • EP300 (E1A binding protein p300)

TP53 mutation • EGFR mutation • HER-2 mutation • KIT mutation • ALK mutation

Immune dysregulation in thymoma: a potential mechanistic link to secondary lung cancer-a case report. (PubMed, Mediastinum)

Recognition of this relationship is important for clinical management, long-term surveillance, and therapeutic decision-making in patients with thymoma. Future studies are warranted to further define the oncogenic consequences of thymic dysfunction and its implications for cancer development.

8 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1)

PD-L1 expression • HER-2 mutation

Deciphering RTK-RAS and MAPK Pathway Dependencies in Gemcitabine-Treated Pancreatic Ductal Adenocarcinoma Through Conversational Artificial Intelligence. (PubMed, Int J Mol Sci)

These findings reveal age- and treatment-dependent pathway dependencies beyond canonical KRAS status and support a precision oncology framework in PDAC. Conversational AI facilitated rapid, multidimensional clinical-genomic integration to uncover clinically relevant signaling substructures.

9 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • RET (Ret Proto-Oncogene)

TP53 mutation • KRAS mutation • HER-2 mutation • RET mutation

gemcitabine